Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Kyverna Therapeutics announced presentation of encouraging one-year data from its pivotal Phase 2 trial of miv-cel, a CD19 CAR T-cell therapy, in stiff person syndrome (SPS), showing sustained clinical benefit and a favorable safety profile. Additionally, updated positive Phase 1 data in progressive multiple sclerosis (MS) will be shared. These res…